 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...45678910111213141516» |
- Tivicay (dolutegravir) / ViiV Healthcare
Lung Transplant in HIV-Infected Patients. Single Centre Experience () - Apr 26, 2020 - Abstract #ISHLT2020ISHLT_240;
At the end of the study the other four patients have been discharged and are improving the pulmonary function tests (Table 2). Conclusion The experience of the first five VIH LT patients in Spain shows that LT is feasible without increasing the risk of infectious or immunological complications.
- || Clinical, Journal: Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients. (Pubmed Central) - Apr 24, 2020
Thus, we performed a 24-week real-life observational study to assess efficacy and safety of switching from raltegravir plus etravirine to dolutegravir plus rilpivirine in 7 previously heavily treated patients. This simplification strategy reduced pill burden and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping.
- | Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date, Trial primary completion date: More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (clinicaltrials.gov) - Apr 24, 2020
P1/2, N=155, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This simplification strategy reduced pill burden and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping. Trial completion date: Aug 2023 --> Apr 2026 | Trial primary completion date: Apr 2021 --> May 2022
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Trial completion date, Trial primary completion date: POPARV: Population Pharmacokinetics of Antiretroviral in Children (clinicaltrials.gov) - Apr 21, 2020
P=N/A, N=700, Recruiting, Sponsor: Assistance Publique - H
Trial completion date: Aug 2023 --> Apr 2026 | Trial primary completion date: Apr 2021 --> May 2022 Trial completion date: Jun 2019 --> Jun 2022 | Trial primary completion date: Jun 2019 --> Jun 2022
- | Edurant (rilpivirine) / J&J
Trial completion, Trial completion date, Trial primary completion date: A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1 (clinicaltrials.gov) - Apr 20, 2020
P3, N=482, Completed, Sponsor: Janssen R&D Ireland
Trial completion date: Jun 2019 --> Jun 2022 | Trial primary completion date: Jun 2019 --> Jun 2022 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Feb 2020 | Trial primary completion date: Dec 2020 --> Feb 2020
- | Edurant (rilpivirine) / J&J
Journal: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivirine/Emtricitabine in Digital Pills. (Pubmed Central) - Apr 16, 2020
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Feb 2020 | Trial primary completion date: Dec 2020 --> Feb 2020 TFV overencapsulated in digital pills are bioequivalentce to TFV in commercial formulations.
- | Edurant (rilpivirine) / J&J
Journal: Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection. (Pubmed Central) - Apr 16, 2020
TFV overencapsulated in digital pills are bioequivalentce to TFV in commercial formulations. This dual therapy combination of DTG-RPV provides maintenance of virological suppression as a switch strategy with few drug interactions and positive effects on lipids and renal and bone health.
- || Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J
Clinical, P2 data, Journal: Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. (Pubmed Central) - Apr 14, 2020
Overall, despite more injection site reactions and pain in the participants receiving RPV LA the injections were well tolerated. Data from this study support the further development of injectable PrEP agents.
- | Journal: Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. (Pubmed Central) - Apr 12, 2020
Interestingly, 8A: was highly cytotoxicity against MOLT-3 (acute lymphoblastic leukemia), with an IC of 4.63±0.62 µg/mL, which was similar with that in EFV and TMC278 (IC 7.76±0.37 and 1.57±0.20 µg/ml, respectively). Therefore, these analogs of the synthesized compounds can serve as excellent bases for the development of new anti-HIV-1 agents in the near future.
- | Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: Contribution of Dolutegravir to Obesity and Cardiovascular Disease (clinicaltrials.gov) - Apr 8, 2020
P4, N=30, Not yet recruiting, Sponsor: Augusta University
- | Edurant (rilpivirine) / J&J
Enrollment change: DRV/r + RPV QD: Efficacy and Toxicity Reduction (clinicaltrials.gov) - Apr 2, 2020
P3, N=37, Completed, Sponsor: ASST Fatebenefratelli Sacco
Therefore, these analogs of the synthesized compounds can serve as excellent bases for the development of new anti-HIV-1 agents in the near future. N=132 --> 37
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. (Pubmed Central) - Apr 1, 2020
P3b
N=132 --> 37 This study supports LDV/SOF co-administered with an F/TAF-based regimen in HIV-1/HCV-GT1 co-infected patients.
- | lamivudine / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare
Retrospective data, Journal: Retrospective Study On The Outcomes Of Two-drugs Regimens Based On Dolutegravir Plus One Reverse Transcriptase Inhibitor In Virologically Suppressed, HIV-Infected Patients. (Pubmed Central) - Mar 26, 2020
VF was infrequent with these regimens and was negatively associated with duration of viral undetectability. Drug-resistance mutations selected at failure of these regimens were those expectable in case of failure of any regimen including DTG, 3TC or RPV, but the impact of resistance to nucleoside reverse transcriptase inhibitors on efficacy of DTG+3TC seems lower than expected.
- | cabotegravir (GSK1265744) / ViiV Healthcare
Clinical Trial,Phase III, Journal: Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. (Pubmed Central) - Mar 26, 2020
P3
Injection-site reactions were common. (Funded by ViiV Healthcare and Janssen; FLAIR ClinicalTrials.gov number, NCT02938520.).
- || cabotegravir (GSK1265744) / ViiV Healthcare
Clinical, Clinical Trial,Phase III, Journal: Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. (Pubmed Central) - Mar 26, 2020
P3
Injection-related adverse events were common but only infrequently led to medication withdrawal. (Funded by ViiV Healthcare and Janssen; ATLAS ClinicalTrials.gov number, NCT02951052.).
- || lamivudine / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. (Pubmed Central) - Mar 24, 2020
(Funded by ViiV Healthcare and Janssen; ATLAS ClinicalTrials.gov number, NCT02951052.). DTG+RPV and DTG+3TC were compared in populations with different characteristics in clinical practice: both regimens showed good effectiveness and improved lipid profile.
- | Edurant (rilpivirine) / J&J
Enrollment open, HEOR, Real-world evidence: 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor (clinicaltrials.gov) - Mar 23, 2020
P=N/A, N=1, Recruiting, Sponsor: ViiV Healthcare
DTG+RPV and DTG+3TC were compared in populations with different characteristics in clinical practice: both regimens showed good effectiveness and improved lipid profile. Not yet recruiting --> Recruiting
- || cabotegravir (GSK1265744) / ViiV Healthcare, Edurant (rilpivirine) / J&J
#VisualAbstract: Long-Acting Cabotegravir and Rilpivirine for HIV-1 (Twitter) - Mar 22, 2020
- || cabotegravir (GSK1265744) / ViiV Healthcare, Edurant (rilpivirine) / J&J, rifampicin / Generic mfg.
PK/PD data, Journal: Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using PBPK modelling. (Pubmed Central) - Mar 18, 2020
The developed PBPK models predicted the theoretical effect of rifampicin on cabotegravir and rilpivirine LA IM formulations. According to these simulations it is likely that co-administration of rifampicin with these LA formulations will result in sub-therapeutic concentrations of both drugs.
- || Clinical, Journal: Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. (Pubmed Central) - Mar 12, 2020
In patients with baseline diagnosis of hypercholesterolemia (TC>200 mg/dl, N = 87), there was no significant change in TC (224 ±2.2 to 228 ±3.4 mg/dl, p = 0.286) or LDL (150±2.5 to 151±3.2 mg/dl, p = 0.751), while HDL increased from 51 ±1.6 to 55 ±1.7 mg/dl (p<0.0001) and both LDL/HDL and TC/HDL ratio decreased significantly, from 3.2±0.1 to 3.0 ±0.1 (p = 0.025) and from 4.7±0.1 to 4.4 ±0.1 (p = 0.004). In this real life study, a slight increase in lipids was found after switching from RPV/FTC/TDF to RPV/FTC/TAF, but these results were not confirmed in people with hypercholesterolemia, in which lipids did not change and LDL/HDL and TC/HDL ratio decreased.
- | Journal: NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal. (Pubmed Central) - Mar 10, 2020
In this real life study, a slight increase in lipids was found after switching from RPV/FTC/TDF to RPV/FTC/TAF, but these results were not confirmed in people with hypercholesterolemia, in which lipids did not change and LDL/HDL and TC/HDL ratio decreased. This work supports the notion that select NNRTIs might help promote the elimination of HIV-1 producing cells as an adjuvant during shock and kill therapy.
- || cabotegravir (GSK1265744) / ViiV Healthcare, Edurant (rilpivirine) / J&J
#CROI2020: An international team of investigators shares 48-week results from ATLAS-2M, which tested out every other month dosing of long-acting injectable cabotegravir/rilpivirine compared with monthly dosing. @overton_edgar https://t.co/bPajG7xlC0 (Twitter) - Mar 9, 2020
- || Clinical, Journal: Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors. (Pubmed Central) - Mar 8, 2020
This work supports the notion that select NNRTIs might help promote the elimination of HIV-1 producing cells as an adjuvant during shock and kill therapy. The choice of initial ART regimens is consistent with Spanish guidelines' recommendations, but is also clearly influenced by physician's perception based on patient's clinical and sociodemographic variables and by the prescribing hospital location.
- ||| cabotegravir (GSK1265744) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection | NEJM https://t.co/d96pTHiqvt Great to see the FLAIR trial published in @NEJM. A "game changer" beginning the era of LA ARV therapy. (Twitter) - Mar 4, 2020
- |||| cabotegravir (GSK1265744) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Clinical: Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression | NEJM https://t.co/eOMnoWoTtZ Great to finally see published the ATLAS study. A "Game changer" in ART with the start of the age of LA agents. (Twitter) - Mar 4, 2020
- ||| cabotegravir (GSK1265744) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Clinical: Simplified treatment regimens for HIV management may increase adherence. In this open label RCT, longer-acting (monthly) injectable cabotegravir plus rilpivirine were compared to standard oral treatment. At 48 weeks similar viral suppression was seen. (Twitter) - Mar 4, 2020
- [VIRTUAL] MAJOR VASCULAR EVENTS IN ADULTS ON ART IN A SOUTH AFRICAN HIV MANAGEMENT PROGRAMME ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_1284;
Stroke predominated, in contrast to high-income settings, where coronary disease is more common. The MVE associations with specific ART regimens we identified deserve further study.
- cabotegravir (GSK1265744) / ViiV Healthcare
[VIRTUAL] HIV A1 OR B DO NOT DIFFERENTIALLY IMPACT CABOTEGRAVIR IN VITRO POTENCY OR DURABILITY ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_1232;
A total of 3/283 (1%) participants (PTS) who received CAB+RPV LA had confirmed virologic failure (CVF)...However, our evaluations cannot determine if HIV subtype A1 with L74I has greater likelihood of selection of additional INSTI mutations under selection pressure. Other factors may contribute to the risk of CVF and require further investigation.
- Prezcobix (darunavir/cobicistat) / Gilead, J&J, Tivicay (dolutegravir) / ViiV Healthcare, abacavir / Generic mfg.
[VIRTUAL] CLINICAL FEATURES AND OUTCOMES OF PATIENTS STOPPING DTG FOR NEUROPSYCHIATRIC SYMPTOMS ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_1212;
In several, but not all, cohorts a high rate of discontinuation for neuropsychological side effects (NPS) has been reported: age, female gender, older age and abacavir co-administration have been suggested as potential risk factors while pharmacological and genetic features are still under study...Patients were switched to raltegravir (30.3%), elvitegravir/cobicistat (28.8%), darunavir/cobicistat (25.8%) or rilpivirine (12.1%)-containing regimens...In our cohort study 11.7% of participants stopped DTG due to NPS: they were mostly sleep disorders and headache and a full regression of both was observed after switching to other drugs. In most cases a complete resolution of symptoms was observed; the incomplete resolution in almost one third of participants suggests alternative reasons.
- [VIRTUAL] TOXICITY OF INTEGRASE INHIBITORS IN A HUMAN EMBRYONIC STEM-CELL MODEL ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_988;
The Tsepamo study reported a signal for risk of neural tube defects in infants exposed to the InSTI dolutegravir (DTG) from conception...CA1S hESCs were cultured (n=5 independent experiments) in the presence of 0.1% DMSO or 1X Cmax of the following regimens: DTG, raltegravir (RAL), bictegravir (BIC), cobicistat-boosted elvitegravir (EVG/COBI), or efavirenz (EFV) on a TDF/FTC backbone; DTG, RAL, BIC, EVG/COBI, or rilpivirine (RPV) on a TAF/FTC backbone; DTG, RAL, or ritonavir-boosted darunavir (DRVr) on an ABC/3TC backbone; cabotegravir (CAB)/RPV...Our results further suggest that exposure to the InSTIs DTG and CAB can induce hESC differentiation. Given the increasing use of DTG and other InSTIs, it is imperative to investigate their long-term safety in the context of pregnancy and embryonic development.
- Edurant (rilpivirine) / J&J
[VIRTUAL] RILPIVIRINE IN HIV-1–INFECTED WOMEN INITIATING PREGNANCY: TO SWITCH OR NOT TO SWITCH? ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_974;
Continuing RPV in virologically-suppressed women initiating pregnancy may be associated with better virological outcome than changing cART. Larger studies are required to confirm these results and establish the safety of fetal exposure to RPV in the long term.
- [VIRTUAL] RACE IMPACT ON DOLUTEGRAVIR-ASSOCIATED WEIGHT GAIN AMONG PREVIOUSLY ART-NAIVE PLWH ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_951;
ART regimens included efavirenz, rilpivirine, atazanavir, darunavir, and DTG-based ≥3 drug regimens...We conducted sensitivity analyses including baseline HIV disease severity as measured by lowest CD4 count (cells/mm3) and limiting regimens to tenofovir (TDF) with emtricitabine/lamivudine backbones...Black PLWH had an increased risk of substantial weight gain compared to white PLWH in their first year after DTG initiation. Additional studies are needed to clarify reasons for racial disparities.
- lamivudine / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] VIROLOGIC FAILURE AND RESISTANCE IN DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_873;
P=N/A
DTX/xTC was associated with slightly lower VF rate than DTG/RPV and the absence of RAM emergence at VF. ARV history are prior VF are key issues to consider before offering 2DR maintenance.
- lamivudine / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
[VIRTUAL] EFFICACY AND DURABILITY OF 2-DRUG VS 3-DRUG InSTI-BASED REGIMENS: DATA FROM REAL LIFE ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_871;
In our real-life setting, both 2DR and 3DR InSTI-based regimens showed high efficacy and durability. Regimens including DTG were associated with a lower risk of VF and discontinuation
- Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] HIV-1 REPLICATION AT <50 C/ML TO 148 WEEKS FOR SWORD-1/SWORD-2 STUDIES WITH DTG+RPV ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_867;
The frequency of participants with TND status under DTG+RPV remained high across all visits with no decline observed through 148 weeks. This is supportive evidence that long term treatment with DTG+RPV is efficacious in virologic suppression to <50c/mL.
- Edurant (rilpivirine) / J&J
[VIRTUAL] BENEFITS OF RILPIVIRINE FOR LIVER FIBROSIS IN HIV/HCV COINFECTED SUBJECTS ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_535;
This difference in the case group was found only in subjects who had CHC, mean difference of -2.9Kpa ([CI95% -4.6 - -1.3]; p <0.01). In patients co-infected with HIV / HCV receiving an ART based on RPV, a significant reduction in liver stiffness measured by TE was observed.
- [VIRTUAL] HEPATIC STEATOSIS ASSOCIATED WITH EXPOSURE TO ELVITEGRAVIR AND RALTEGRAVIR ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_534;
Moderate-severe hepatic steatosis in PLWH without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir and raltegravir. Prospective trials are required to establish a causal association.
- Edurant (rilpivirine) / J&J
[VIRTUAL] TRENDS IN TRANSMITTED DRUG RESISTANCE IN SPAIN THROUGH THE PERIOD 2007-2018 ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_513;
Clinically Relevant resistance to recommended first line regimens showed a slow decline from 2007-2012, and peaked in 2013-2014 due to the inclusion of Rilpivirine for 1st line in the Spanish recommendations...Resistance to INsTIs remains at very low levels. These findings, together with the very low prevalence of resistance to recommended first line NRTIs in 2015-2018 reinforce GESIDA recommendations on baseline resistance testing and test and treat strategies when starting PIs or INsTIs based regimens.
- cabotegravir (GSK1265744) / ViiV Healthcare
[VIRTUAL] LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_509;
P3
Although ISRs were frequently reported with CAB+RPV LA, they seldom led to withdrawal, and overall treatment satisfaction was higher than with ART. These results attest to the durability of CAB+RPV LA.
- [VIRTUAL] CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_366;
Both CAB and RPV have a low drug interaction potential as perpetrators. Alternative ART selection after discontinuing CAB LA + RPV LA may include CYP3A and/or UGT1A1 inducers or inhibitors, without efficacy or safety concerns despite potential for transient increases in CAB and RPV concentrations by inhibitors.
- cabotegravir (GSK1265744) / ViiV Healthcare, Edurant (rilpivirine) / J&J
CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION (Ballroom B) - Mar 2, 2020 - Abstract #CROI2020CROI_365;
- cabotegravir (GSK1265744) / ViiV Healthcare, Edurant (rilpivirine) / J&J
[VIRTUAL] CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY: ATLAS-2M STUDY ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_156;
Q8W dosing of CAB+RPV LA was noninferior to Q4W dosing and well tolerated. These results support the therapeutic potential of CAB+RPV LA administered every 2 months.
- || Edurant (rilpivirine) / J&J
Clinical, Journal: Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice. (Pubmed Central) - Mar 2, 2020
P=N/A
In RLS where integrase inhibitors are not affordable, RPV-based regimens are a good alternative option for PLHIV who cannot tolerate first-line NNRTI or boosted PI regimen, without prior NNRTI/PI resistance. Trial registration HIV-NAT 006 cohort, clinical trial number: NCT00411983.
- | cabotegravir (GSK1265744) / ViiV Healthcare
Journal: A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor. (Pubmed Central) - Mar 2, 2020
This kind of combinational treatment shows promising results also against drug-resistant HIV. Cabotegravir in combination with rilpivirine is an interesting therapeutic, due to the possibility of formulating long-acting formulation with dosing interval of every 4 weeks or less, thus reducing daily pill burden and improving patient's compliance.
- | Edurant (rilpivirine) / J&J, rilpivirine LA (TMC278 LA) / J&J
Journal: The Use of Droplet Digital PCR to Quantify HIV-1 Viral Replication in the Colorectal Explant Model. (Pubmed Central) - Feb 29, 2020
ddPCR also required less sample and based on p24 vs ddPCR correlation, could potentially reduce the explant culture time from 14 to 10 days (r2=0.78, p<0.001) due to the increased sensitivity of ddPCR. We demonstrate that ddPCR is a suitable alternative to HIV-1 p24 ELISA to quantify HIV-1 infection in the explant model and has the potential to decrease explant culture time.
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Enrollment change, Trial termination, Adverse events: Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting (clinicaltrials.gov) - Feb 27, 2020
P=N/A, N=1, Terminated, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
We demonstrate that ddPCR is a suitable alternative to HIV-1 p24 ELISA to quantify HIV-1 infection in the explant model and has the potential to decrease explant culture time. N=400 --> 1 | Suspended --> Terminated; Unfavourable opinion of ethical comittee for Amendment Nr 3
- | efavirenz / Merck (MSD), Generic mfg., Edurant (rilpivirine) / J&J, nevirapine / Generic mfg.
Journal: Nonnucleoside reverse transcriptase inhibitors (NNRTI) inhibit reverse transcriptase through a mutually exclusive interaction with divalent cation-dNTP complexes. (Pubmed Central) - Feb 26, 2020
This suggests that K103N overcomes EFV inhibition mostly by binding more weakly to the drug, and is in contrast to other reports that indicate K103N has little of no effect on drug or dNTP binding. Overall this biochemical analysis supports recent biophysical analyses of NNRTI-RT interactions that indicate mutually exclusive binding.
- | Edurant (rilpivirine) / J&J
New trial: Short Cycle Therapy in ART Regimens Containing Rilpivirine: Assessment of Patients' Satisfaction (clinicaltrials.gov) - Feb 24, 2020
P=N/A, N=60, Not yet recruiting, Sponsor: Azienda Ospedaliera Universitaria Integrata Verona
- | Journal: Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. (Pubmed Central) - Feb 23, 2020
Molecular modeling disclosed that the side chain at the C-6 position of DATAs occupied the entrance channel of the HIV-1 reverse transcriptase non-nucleoside binding pocket (NNIBP) attributing to the improved activity. The preliminary structure-activity relationship and PK profiles were also discussed.